Noonan syndrome: lessons learned from genetically modified mouse models.

Area of Science:

• Genetics
• Molecular Biology
• Developmental Biology

Background:

• Noonan syndrome is a RASopathy characterized by activating mutations in the RAS/MAPK signaling pathway.
• Mutations in genes like PTPN11, SOS1, RAF1, and KRAS lead to diverse clinical symptoms including cardiopathies and neurocognitive impairment.
• The genetic variability complicates genotype-phenotype correlation and patient management.

Purpose of the Study:

• To review studies utilizing genetically engineered mouse models (GEMMs) for Noonan syndrome research.
• To assess the contribution of GEMMs in understanding the syndrome's genetic basis and phenotypic manifestations.
• To identify gaps in current research and suggest future directions for GEMM development and application.

Main Methods:

• Review of existing literature on genetically engineered mouse models (GEMMs) for Noonan syndrome.
• Analysis of studies detailing the genetic mutations and resulting phenotypes in these models.
• Evaluation of the utility of GEMMs in elucidating disease mechanisms.

Main Results:

• GEMMs have been instrumental in understanding the roles of specific genes and mutations in Noonan syndrome development.
• Existing models have provided insights into the phenotypic spectrum associated with RAS/MAPK pathway alterations.
• The development of new models through next-generation sequencing is expanding the understanding of rare mutations.

Conclusions:

• GEMMs are valuable tools for studying Noonan syndrome, offering insights into gene function and mutation effects.
• Further characterization of existing GEMMs is needed to fully understand phenotypic modifiers and cancer risks.
• Developing and refining GEMMs is essential for advancing preventative and therapeutic strategies for Noonan syndrome.